nti_article_02

Sunstone BioSciences, Inc.

Sunstone BioSciences, Inc., a cancer treatment company, is currently developing nanoparticles as photosensitizer delivery and activation systems that will allow for preferential tumor uptake. The company’s products have been licensed to a major biopharmaceutical company. Sunstone is a subsidiary of Intelligent Materials Solutions.

www.intmatsol.com

NTI: Signs of Success

NTI research programs have been extremely successful at publishing in peer-reviewed journals, resulting in more than 820 articles.

In addition, NTI researchers have been awarded more than 200 federal grants totaling more than $150 million.